Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Solara Active Pharma Sciences's Days Payable or its related term are showing as below:
BOM:541540'
s Days Payable Range Over the Past 10 Years
Min: 127.2 Med: 136.97 Max: 163.63
Current: 134.26
During the past 10 years, Solara Active Pharma Sciences's highest Days Payable was 163.63. The lowest was 127.20. And the median was 136.97.
BOM:541540's Days Payable is ranked better than 70.09% of 926
companies
in the Drug Manufacturers industry
Industry Median: 90.22
vs BOM:541540: 134.26
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Solara Active Pharma Sciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Solara Active Pharma Sciences Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Solara Active Pharma Sciences's Days Payable distribution charts can be found below:
* The bar in red indicates where Solara Active Pharma Sciences's Days Payable falls into.
Solara Active Pharma Sciences Days Payable Calculation
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Solara Active Pharma Sciences (BOM:541540) has a Days Payable of 127.24 as of Jun. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Solara Active Pharma Sciences and its competitors. This is near median its historical median of 136.97. Over the past decade, Solara Active Pharma Sciences' Days Payable has ranged from 127.20 to 163.63. According to the industry distribution chart, Solara Active Pharma Sciences ranks #277 out of 926 companies in the Drug Manufacturers industry, placing it in the top 29.9%.
Is Solara Active Pharma Sciences' Days Payable too high?
Solara Active Pharma Sciences' current Days Payable of 127.24 is near median its 10-year median of 136.97. Over the past 10 years, this metric has ranged from a low of 127.20 to a high of 163.63. The Drug Manufacturers industry median Days Payable is 90.22. Solara Active Pharma Sciences' value of 127.24 is 41% above this industry median. Based on the distribution chart, Solara Active Pharma Sciences ranks #277 out of 926 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Solara Active Pharma Sciences has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Solara Active Pharma Sciences' Days Payable compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Solara Active Pharma Sciences ranks #277 out of 926 companies for Days Payable. This puts Solara Active Pharma Sciences in the upper half of its industry. The industry median Days Payable is 90.22. Solara Active Pharma Sciences' value of 127.24 is 41% above this benchmark. Historically, Solara Active Pharma Sciences' own Days Payable has ranged from 127.20 to 163.63 over the past decade. While the company's 10-year median is 136.97 vs. the industry median of 90.22, Solara Active Pharma Sciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.22, based on 926 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Solara Active Pharma Sciences's current Days Payable of 127.24 is 41% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Solara Active Pharma Sciences and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.22 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Solara Active Pharma Sciences's current Days Payable is 127.24, which is near median its own 10-year median of 136.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Solara Active Pharma Sciences stock overvalued right now?
Based on GuruFocus' analysis, Solara Active Pharma Sciences (BOM:541540) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹569.84, compared to a current price of ₹502.15 — trading 11.9% below its estimated fair value. The current Days Payable is 127.24, which is near median its 10-year median of 136.97 and 41% above the Drug Manufacturers industry median of 90.22. Solara Active Pharma Sciences' overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Solara Active Pharma Sciences (BOM:541540), the current Days Payable is 127.24 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Solara Active Pharma Sciences (BOM:541540) Overvalued in 2026?
Based on GuruFocus' analysis, Solara Active Pharma Sciences stock appears to be undervalued.
The current stock price of ₹502.15 is trading 11.9% below its estimated GF Value™ of ₹569.84.
GuruFocus considers Solara Active Pharma Sciences to be Modestly Undervalued.
Key valuation signals for BOM:541540:
Days Payable: 127.24 (near median its 10-year median of 136.97)
GF Value™: ₹569.84 vs. price of ₹502.15 (11.9% below fair value)
Industry Position: 41% above the Drug Manufacturers median (#277 of 926)
No single metric tells the full story. See the BOM:541540 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Solara Active Pharma Sciences Ltd is engaged in the Active Pharmaceutical Ingredients (API) in India. It manufactures and develops APIs and offers services, including CRAMS and contract manufacturing for APIs. The company offers products and services, such as Anaesthetic, Analgesics, Antiviral, Retinoid, Anti-emetic, Antimalarial, Diuretic, Muscle relaxant, Antiallergics, Antihypertensive, Calcimimetic agent, Anti-seizure, Antigout, Cardiovascular, Anti-infective, Cough suppressant, and others. It also offers contract services, including contract development and manufacturing, and analytical services. Geographically, the company generates all of its revenue from India.
69GF Score
Get the complete analysis for BOM:541540
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:541540 has been successfully added to your 
